eHIV Review

Clinical Uses of LA Injectable ART

Editor's note:

Just prior to publication of this issue, the FDA approved direct-to-inject administration of cabotegravir/rilpivirine (Cabenuva), without an initial oral lead-in period. This is an update from the information Dr. Tanyaporn Wansom presents in this issue, and means that as of March 24, 2022, it is appropriate to consider initiation of injectable long-acting cabotegravir and rilpivirine without first giving pills of the drugs to confirm tolerability. Learners are advised to review the updated Cabenuva prescribing information for additional guidance.

In this issue:

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting ART actually mean in practice?

Join us for this eHIV Review podcast, as Dr. Tanyaporn Wansom, Senior Infectious Diseases Consultant at Chayun Consulting in Bangkok Thailand, takes us to the clinic to answer some of these key questions.

Learning objectives:

• Identify patients who would be eligible to switch to long-acting cabotegravir and rilpivirine.
• Describe the potential uses of long-acting injectable HIV agents for pre-exposure prophylaxis.